GT Biopharma: Up on prelim data from cancer drug study
17/03/2021 12:46
** Drug developer's shares GTBP.O rise 8.4% to $6.83
premarket
** Co reports updated interim data from ongoing early-to-mid
stage study of its lead experimental treatment, GTB-3550, in
patients with certain types of bone marrow-related cancer (https://refini.tv/2NtGn6k)
** Study has enrolled nine patients so far
** Three of the five patients receiving increasing dose of
GTB-3550 experienced reduction in abnormal white blood cells in
bone marrow - GTBP
** All patients treated did not show any signs of cytokine
release syndrome or inflammatory response to the drug
** Stock down ~13% this year, as of last close
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))